Minidiab (Glipizide)

Glipizide, the active ingredient in Minidiab, is a sulfonylurea presented as an oral tablet for oral use. It lowers blood glucose by stimulating insulin release from pancreatic beta cells and is indicated for the management of type 2 diabetes mellitus in adult patients. It is prescribed when diet and exercise alone are insufficient to achieve glycemic targets.

GNH USA supplies Minidiab as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU GMP standards and providing the product to hospitals, pharmacies and clinics worldwide through regulated distribution channels.

Glipizide is an oral sulfonylurea used to improve glycemic control in type 2 diabetes mellitus. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose by enhancing insulin secretion from pancreatic beta cells. - Inadequate glycemic control on metformin: adds an additional glucose‑lowering effect when combined with metformin therapy in adults. - Adults with diet‑controlled hyperglycemia: assists in achieving target HbA1c when lifestyle measures alone are insufficient. - Elderly patients with type 2 diabetes: provides effective glucose reduction, though dose may need adjustment and hypoglycemia risk requires monitoring.

Glipizide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hypoglycemia: feeling of low blood sugar, dizziness, sweating, or tremor. - Weight gain: modest increase in body weight during therapy. - Nausea: mild stomach upset or queasiness. - Headache: transient head pain.

Serious or Rare Side Effects: - Severe hypoglycemia: prolonged low blood sugar requiring medical assistance. - Allergic reactions: rash, itching, swelling, or rare anaphylaxis. - Blood dyscrasias: leukopenia, thrombocytopenia, or agranulocytosis.

When prescribing glipizide, clinicians should consider several safety measures to minimize risk. - Dose adjustment in renal impairment: reduce dose or avoid in severe renal failure. - Monitor blood glucose regularly: to detect hypoglycemia early. - Use caution in elderly patients: increased sensitivity to hypoglycemia. - Avoid concomitant use with other sulfonylureas: risk of additive hypoglycemia. - Store at room temperature: keep in original container, protect from moisture and light.

Glipizide can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Concurrent use with other sulfonylureas: additive hypoglycemia risk. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone): increase glipizide plasma levels. - Insulin therapy: may cause severe hypoglycemia.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycemia. - Thiazide diuretics: can diminish glucose‑lowering effect. - Alcohol: may potentiate hypoglycemia, especially with fasting.